Últimas noticias

9th junio 2020

Curium Announces Drug Master File and Active Substance Master File for Germanium-68 in the U.S. and Europe

16th abril 2020

Un mensaje de Curium sobre el COVID-19 y nuestras acciones

24th marzo 2020

Curium Announces Approval of Pulmotech^TM MAA (kit for the preparation of technetium Tc 99m albumin aggregated injection) by the U.S. Food and Drug Administration

12th marzo 2020

RadioMedix and Curium Announce copper Cu 64 dotatate injection Was Granted Priority Review by the U.S. FDA

3rd marzo 2020

Curium Acquires Zevacor Molecular Strengthening Its PET Portfolio

30th enero 2020

Curium is attending these global congresses in 2020

7th enero 2020

RadioMedix and Curium Announce FDA Filing of copper Cu 64 dotatate injection New Drug Application

2nd diciembre 2019

Curium Acquires Finnish Radiopharmaceuticals Company MAP Medical Technologies Oy

16th noviembre 2019

CEO Today Healthcare Awards Winner 2019

13th noviembre 2019

Curium Announces Plan to Submit an Application to Market Generic Ioflupane I 123 Injection in the U.S.

4th septiembre 2019

Curium Announces Revised Pricing for Technescan MAG3^TM (kit for the preparation of technetium Tc 99m mertiatide)

22nd febrero 2019

Curium is attending these global congresses in 2019

13th febrero 2019

Campaign to Support FDA Approved Products

5th febrero 2019

Curium Petten and NRG Agreement

6th septiembre 2018

Renaud Dehareng de Curium recibe el galardón CEO Healthcare Award 2018

27th agosto 2018

Curium y RadioMedix anuncian un acuerdo global en exclusiva para el desarrollo de ⁶⁴Cu-Dotatate

10th mayo 2018

Curium Expands Nuclear Medicine Offerings, Announces U.S. Availability of Xenon Xe 133 Gas

2nd mayo 2018

Curium enhances its position in the French PET market with the completion of the acquisition of Cyclopharma’s French commercial and manufacturing operations

11th abril 2018

Curium adquiere las operaciones comerciales y de fabricación de Cyclopharma en Francia.

26th marzo 2018

Moving on from Mallinckrodt: Curium eyes $650 million in radiopharmaceuticals sales